Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Other Non-Current Liabilities (2018 - 2025)

Historic Other Non-Current Liabilities for Ocular Therapeutix (OCUL) over the last 10 years, with Q4 2025 value amounting to $13.9 million.

  • Ocular Therapeutix's Other Non-Current Liabilities rose 496.0% to $13.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $13.9 million, marking a year-over-year increase of 496.0%. This contributed to the annual value of $13.9 million for FY2025, which is 496.0% up from last year.
  • Latest data reveals that Ocular Therapeutix reported Other Non-Current Liabilities of $13.9 million as of Q4 2025, which was up 496.0% from $15.0 million recorded in Q3 2025.
  • Ocular Therapeutix's 5-year Other Non-Current Liabilities high stood at $73.3 million for Q1 2021, and its period low was $6.4 million during Q4 2022.
  • Over the past 5 years, Ocular Therapeutix's median Other Non-Current Liabilities value was $14.2 million (recorded in 2024), while the average stood at $21.8 million.
  • In the last 5 years, Ocular Therapeutix's Other Non-Current Liabilities crashed by 8253.62% in 2022 and then soared by 37216.19% in 2023.
  • Over the past 5 years, Ocular Therapeutix's Other Non-Current Liabilities (Quarter) stood at $20.2 million in 2021, then tumbled by 68.55% to $6.4 million in 2022, then surged by 372.16% to $30.0 million in 2023, then tumbled by 55.83% to $13.2 million in 2024, then grew by 4.96% to $13.9 million in 2025.
  • Its Other Non-Current Liabilities was $13.9 million in Q4 2025, compared to $15.0 million in Q3 2025 and $14.0 million in Q2 2025.